Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Public ClinicalTrials.gov record NCT01500278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding adequately to MTX.
Study identification
- NCT ID
- NCT01500278
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 915 participants
Conditions and interventions
Conditions
Interventions
- Certolizumab Pegol (CZP) Biological
- Adalimumab (ADA) Biological
- Methotrexate (MTX) Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2011 (Type not available)
- Primary completion
- Nov 2015 (Actual)
- Completion
- Jan 2016 (Actual)
- Last update posted
- Jul 31, 2018
2011 – 2016
United States locations
- U.S. sites
- 62
- U.S. states
- 27
- U.S. cities
- 59
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 141 | Birmingham | Alabama | — | — |
| 214 | Tuscaloosa | Alabama | — | — |
| 159 | Tucson | Arizona | — | — |
| 152 | Hot Springs | Arkansas | — | — |
| 147 | Covina | California | — | — |
| 161 | Fullerton | California | — | — |
| 217 | La Mesa | California | — | — |
| 149 | Los Angeles | California | — | — |
| 144 | Menifee | California | — | — |
| 185 | Roseville | California | — | — |
| 208 | Sacramento | California | — | — |
| 189 | Van Nuys | California | — | — |
| 148 | Whittier | California | — | — |
| 220 | Lewes | Delaware | — | — |
| 142 | Aventura | Florida | — | — |
| 216 | Fort Lauderdale | Florida | — | — |
| 162 | Gainesville | Florida | — | — |
| 209 | Vero Beach | Florida | — | — |
| 145 | Coeur d'Alene | Idaho | — | — |
| 202 | Maywood | Illinois | — | — |
| 134 | Lexington | Kentucky | — | — |
| 178 | Baltimore | Maryland | — | — |
| 137 | Battle Creek | Michigan | — | — |
| 153 | Detroit | Michigan | — | — |
| 155 | Lansing | Michigan | — | — |
| 204 | Eagan | Minnesota | — | — |
| 180 | Rochester | Minnesota | — | — |
| 143 | Saint Louis Park | Minnesota | — | — |
| 135 | Omaha | Nebraska | — | — |
| 170 | Reno | Nevada | — | — |
| 201 | Teaneck | New Jersey | — | — |
| 150 | Voorhees Township | New Jersey | — | — |
| 205 | Albuquerque | New Mexico | — | — |
| 154 | Albany | New York | — | — |
| 136 | Brooklyn | New York | — | — |
| 219 | Orchard Park | New York | — | — |
| 207 | Plainview | New York | — | — |
| 167 | Syracuse | New York | — | — |
| 140 | Cincinnati | Ohio | — | — |
| 184 | Oklahoma City | Oklahoma | — | — |
| 164 | Bethlehem | Pennsylvania | — | — |
| 132 | Duncansville | Pennsylvania | — | — |
| 190 | Wyomissing | Pennsylvania | — | — |
| 210 | Charleston | South Carolina | — | — |
| 187 | Myrtle Beach | South Carolina | — | — |
| 203 | Orangeburg | South Carolina | — | — |
| 133 | Jackson | Tennessee | — | — |
| 160 | Knoxville | Tennessee | — | — |
| 138 | Austin | Texas | — | — |
| 151 | Corpus Christi | Texas | — | — |
| 131 | Dallas | Texas | — | — |
| 146 | Dallas | Texas | — | — |
| 213 | Dallas | Texas | — | — |
| 166 | Houston | Texas | — | — |
| 212 | Houston | Texas | — | — |
| 139 | San Antonio | Texas | — | — |
| 181 | Sugar Land | Texas | — | — |
| 165 | Victoria | Texas | — | — |
| 211 | Arlington | Virginia | — | — |
| 157 | Spokane | Washington | — | — |
| 163 | Clarksburg | West Virginia | — | — |
| 215 | Glendale | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 113 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01500278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2018 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01500278 live on ClinicalTrials.gov.